Hyderabad, 10 November, 2021 – The World Health Organization (WHO) has listed India’s COVID-19 vaccine made by Bharat Biotech for emergency use. The vaccine was approved for emergency use in India in January 2021, while the third phase of clinical trials was still under way. The WHO’s expert panel, which authorises emergency use internationally, stated:
- The vaccine was recommended for use in two doses, with a dose interval of four weeks, in all age groups 18 and above
- Covaxin had 78% efficacy against Covid 19 of any severity, 14 or more days after the second dose, and is suitable for low- and middle-income countries due to easy storage
This vaccine named Covaxin®, is a whole virion inactivated vaccine against SARS-CoV2, which Bharat Biotech developed in partnership with Indian state research bodies, ICMR and NIV. Covaxin has demonstrated 65.2 per cent protection against the new Delta variant. To date India has administered more than 110 million Covaxin doses so far, accounting for 12% of the 985.5 million total doses administered in India, and has also been exported.
More information at https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin-annexes ; https://www.bharatbiotech.com/covaxin.html ; https://www.bharatbiotech.com/images/press/covaxin-who-approval-press-release.pdf ; https://www.hindustantimes.com/india-news/who-accepts-bharat-biotech-s-covaxin-for-emergency-use-listing-101635939673269.html ;
Attached documents
